NCT00079391View on ClinicalTrials.gov

Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignancies

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

December 31, 2008

Study Completion Date

September 30, 2011

Conditions
Hematologic MalignanciesBone Marrow Transplant Rejection
Interventions
DEVICE

allogeneic hematopoietic stem cell transplantation

Manipulated Peripheral Blood Stem Cell graft on Day 0. Target CD34+ dose 6 x10e6/kg, (range 3 to 8x10e6/kg) CD3+ dose fixed to 2 x 10e4/kg.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH

NCT00079391 - Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignancies | Biotech Hunter | Biotech Hunter